CSIMarket Company Name, Ticker, Industry, else..


Orgenesis Inc  (ORGS)
Other Ticker:  
 

Orgenesis Inc

ORGS's Fundamental analysis



Looking into Orgenesis Inc growth rates, revenue grew by 215.45 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 3307

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.76 %

Orgenesis Inc's net income grew by 148.75 % in III. Quarter 2024 year on year, above company average,

• More on ORGS's Growth


Orgenesis Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 51.63 in trailing twelve-month period.
Company
0.47
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 16.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.


• More on ORGS's Valuation
 
 Total Debt (Millions $) 13
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 6,774
 Net Income/Employee (TTM) $ 241,507
 Receivable Turnover (TTM) 5.39
 Tangible Book Value (Per Share $) -7.14

Orgenesis Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 51.63 in trailing twelve-month period.
Company
0.47
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 16.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.


• More on ORGS's Valuation

•  Market Capitalization (Millions $) 16
•  Shares Outstanding (Millions) 5
•  Employees 146
•  Revenues (TTM) (Millions $) 1
•  Net Income (TTM) (Millions $) 35
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) 13
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 6,774
•  Net Income/Employee(TTM) $ 241,507
•  Receivable Turnover Ratio (TTM) 5.39
•  Tangible Book Value (Per Share $) -7.14

•  Market Capitalization (Millions $) 16
•  Shares Outstanding (Millions) 5
•  Employees 146
•  Revenues (TTM) (Millions $) 1
•  Net Income (TTM) (Millions $) 35
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) 0


    ORGS's Profitability Comparisons
Orgenesis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 2419.02 % from 1727.64 % in II. Quarter.

Orgenesis Inc net profit margin of 2670.32 % is currently ranking no. 4 in Major Pharmaceutical Preparations industry, ranking no. 6 in Healthcare sector and number 16 in S&P 500.


Profitability by Segment
Total 2670.32 %



  Ratio
•   Capital Ratio (MRQ) 0.07
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.04
•  Inventory Turnover Ratio (TTM) -



Orgenesis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 2419.02 % from 1727.64 % in II. Quarter.

Orgenesis Inc net profit margin of 2670.32 % is currently ranking no. 4 in Major Pharmaceutical Preparations industry, ranking no. 6 in Healthcare sector and number 16 in S&P 500.

• More on ORGS's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com